Your session is about to expire
← Back to Search
Tumor Cell Vaccine + Cytoxan for Neuroblastoma (ATOMIC Trial)
ATOMIC Trial Summary
This trial is testing an experimental treatment for neuroblastoma, which is a solid tumor that is the second most common cancer in children. The treatment consists of a series of immunizations using a tumor vaccine, combined with low-dose chemotherapy taken by mouth on a daily basis. The hope is that the vaccine will cause the immune system to recognize and kill more types of neuroblastoma tumors. Additionally, the immunizations will be combined with daily low dose chemotherapy.
ATOMIC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowATOMIC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ATOMIC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am HIV positive.I am able to live with some level of independence.My neuroblastoma is high risk and has either come back, didn't respond to treatment, or I couldn't complete standard therapy.I was diagnosed before turning 21.My kidney function is within the required range.I am not pregnant and will use effective birth control during the study.I do not have any severe infections or uncontrolled conditions that would stop me from following the study's requirements.I have taken oral cytoxan for over 2 months in the last 6 months.I have recovered from my last cancer treatment.
- Group 1: Treatment Plan
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are currently involved in this trial?
"Unfortunately, this research has concluded its recruitment phase. The trial was initially announced on September 1st 2010 and the information was last updated on March 25th 2022. Fortunately, there are still many other medical trials including 161 studies related to Neuroblastoma and 816 involving a Neuroblastoma Vaccine (unmodified SKNLP with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) that have ongoing patient enrollment."
Is enrollment still available for this clinical experiment?
"Clinicaltrials.gov data suggests that this medical trial is not currently recruiting participants as of March 25, 2022; however, there are 977 other trials actively looking for patients at the present moment. The study was initially uploaded on September 1st 2010 and has been updated since then."
What conditions are typically treated via the Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells)?
"Neuroblastoma Vaccine, which consists of unmodified SKNLP and gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells, is often prescribed to patients suffering from multiple sclerosis. In addition, this therapeutic approach can be employed in the management of mixed cell lymphomas, leukemias, myelocytic acutes, and retinoblastomas."
Are there any records of similar research involving Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells?)
"Currently, 816 trials are running to explore the safety and efficacy of Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells). Of these studies, 154 have entered Phase 3. Philadelphia is a major hub for research on this treatment; however 27824 sites worldwide are conducting clinical trials related to it."
Share this study with friends
Copy Link
Messenger